Clinical study
Acute tumor lysis syndrome: A review of 37 patients with Burkitt's lymphoma

https://doi.org/10.1016/0002-9343(80)90286-7Get rights and content

Abstract

Renal and metabolic complications of tumor lysis during 46 episodes of remission induction chemotherapy were reviewed in 37 patients with American Burkitt's lymphoma. Azotemia occurred in 14 patients, preceding chemotherapy in eight. All of these patients had abdominal tumors. Pretreatment azotemia was associated with elevated lactic dehydrogenase (LDH) and uric acid levels, and sometimes extrinsic ureteral obstruction by tumor. Two patients required dialysis for uric acid nephropathy before chemotherapy was initiated. Following chemotherapy, major complications of tumor lysis (hyperuricemia, hyperkalemia and hyperphosphatemia) were associated with very large tumors, high LDH levels and inadequate urinary output. In patients undergoing diuresis and receiving allopurinol, hyperkalemia or hyperuricemia developed infrequently unless concomitant renal failure ensued. Hyperphosphatemia, which occurred only after chemotherapy, developed in 10 of 32 (31 per cent) nonazotemic and in all azotemic patients. Hemodialysis was required in three post-treatment patients for control of azotemia, hyperuricemia, hyperphosphatemia and/or hyperkalemia. Because of the potential for renal failure caused by precipitation of phosphate, severe hyperphosphatemia is an additional criterion for dialysis in patients with acute tumor lysis syndrome.

References (32)

  • FM Muggia et al.

    Hyperphosphatemia and hypocalcemia in neoplastic disorders

    N Engl J Med

    (1974)
  • DS Ettinger et al.

    Hyperphosphatemia, hypocalcemia, and transient renal failure. Results of cytotoxic treatment of acute lymphoblastic leukemia

    JAMA

    (1978)
  • FM Muggia et al.

    Allopurinol in the treatment of neoplastic disease complicated by hyperuricemia

    Arch Intern Med

    (1967)
  • IH Krakoff et al.

    Prevention of hyperuricemia in leukemia and lymphoma. Use of allopurinol, a xanthine oxidase inhibitor

    JAMA

    (1965)
  • C Berard et al.

    Histopathological definition of Burkitt's tumor

    Bull WHO

    (1969)
  • JL Ziegler

    Treatment results of 54 American patients with Burkitt's lymphoma are similar to the African experience

    N Engl J Med

    (1977)
  • Cited by (358)

    • A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia

      2021, Leukemia Research
      Citation Excerpt :

      Overproduction can lead to crystallization in the renal tubules, acute nephropathy, and renal failure which may require the use of renal replacement therapy (hemodialysis). The frequency of acute renal failure, occasionally irreversible, as a result of uric acid nephropathy can be as high as 30 % [5]. Allopurinol, available in the US since 1964, decreases UA formation by inhibiting xanthine oxidase but pre-existing UA is left untargeted [6].

    • Tumour lysis syndrome

      2019, Medicina Clinica
    • Tumor lysis syndrome

      2019, Onco-Nephrology
    • Conventional chemotherapy

      2019, Onco-Nephrology
    • Diagnostic Pathology: Blood and Bone Marrow

      2018, Diagnostic Pathology: Blood and Bone Marrow
    • Oncologic Metabolic Emergencies

      2017, Hematology/Oncology Clinics of North America
    View all citing articles on Scopus
    1

    From the Pediatric Oncology Branch, Division of Cancer Treatment, National Cancer Institute and the Clinical Nephrology Service, National Institute of Allergy and Infectious Disease, Bethesda, Maryland.

    View full text